Article Text

Download PDFPDF
Paraneoplastic cerebellar degeneration in ovarian carcinoma: case report with review of immune modulation
  1. W. H. Bradley,
  2. P. R. Dottino and
  3. J. Rahaman
  1. Department of Obstetrics, Gynecology, and Reproductive Medicine, Mount Sinai Medical Center, New York, New York
  1. Address correspondence and reprint requests to: Jamal Rahaman, MD, 1176 Fifth Avenue, Box 1170, New York, NY 10029. Email: jamal.rahaman{at}mssm.edu

Abstract

Paraneoplastic cerebellar degeneration (PCD) is a rare nonmetastatic complication of a carcinoma. It is typically mediated by antibodies generated against tumor antigens. These antigens are the same proteins as expressed on Purkinje cells within the cerebellum; immune activation in the central nervous system (CNS) results in the syndrome. A 56-year-old woman with stage IIIC serous ovarian carcinoma diagnosed 3 years prior developed progressive limb ataxia. Serum anti-Yo antibodies were positive, confirming the diagnosis of PCD. Treatment with plasmaphoresis, intravenous immune globulin, and immune modulation with corticosteroids and tacrolimus was unsuccessful. Although the syndrome can be debilitating and treatment options are limited, it may also be an example of a successful host immune response in certain cases.

  • ovarian cancer
  • paraneoplastic syndrome
  • cerebellar degeneration

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.